FIA
FBRX icon

FNY Investment Advisers’s Forte Biosciences FBRX Stock Holding History

FNY Investment Advisers’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-383
Closed -$9K – 647
2023
Q2 		$9K Buy
+383
New +$9.95K 0.01% 319
2023
Q1 		– Sell
-300
Closed -$7K – 616
2022
Q4 		$7K Buy
+300
New +$7.69K 0.01% 333

Other funds holding FBRX

TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

FNY Investment Advisers's FBRX Position: Q3 2023 in Review

FNY Investment Advisers sold out of Forte Biosciences (FBRX) in Q3 2023, closing a stake of 383 shares — an estimated $9K sold.

FNY Investment Advisers first reported a position in FBRX in Q4 2022 and held it in 2 quarters. The position peaked at $9K in Q2 2023. 30 funds tracked by Wall St. Rank hold FBRX as of Q3 2023.

  • FNY Investment Advisers reported no remaining Forte Biosciences position as of Q3 2023 after selling out during the quarter.
  • FNY Investment Advisers sold 383 Forte Biosciences shares in Q3 2023, an estimated $9K.
  • FNY Investment Advisers first reported a position in Forte Biosciences in Q4 2022 and held it in 2 quarters.
  • FNY Investment Advisers's Forte Biosciences position peaked at $9K in Q2 2023.
  • 30 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2023.

Based on FNY Investment Advisers's 13F filing for Q3 2023, filed 10 Oct 2023.